Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - CMO Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Dennis Ding - Jefferies David Amsellem - Piper Sandler Operator Thank you for standing by, and welcome to Cara Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time all participants are in ...

Cara Therapeutics (CARA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.51%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.53 per share when it actually produced a loss of $0.52, delivering a surprise of 1.89%.Over the last four quarters, the compa ...

–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a ...

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– STAMFORD, Conn., March 4, 2024 – Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023. 2023 ...

STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Event ...

STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under “Even ...

Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript November 13, 2023 4:30 PM ET Company Participants Matt Murphy - Manager of IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler Annabel Samimy - Stifel Oren Livnat - H.C. Wainwright Operator Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welco ...

CARA THERAPEUTICS, INC. CONDENSED STATEMENTS OF COMPREHENSIVE LOSS (amounts in thousands, excluding share and per share data) (unaudited) Table of Contents 3 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------------------|------------------|-------|----------------------------------|-------------------------|-------|------------------------------------------|------------------------------| | | Common \nShares | Stock \nAmount | | Ad ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Matthew Murphy - Manager, IR Christopher Posner - President, CEO & Director Ryan Maynard - CFO Scott Terrillion - Chief Compliance Officer, General Counsel & Corporate Secretary Conference Call Participants Dennis Ding - Jefferies Annabel Samimy - Stifel, Nicolaus & Company Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler & Co. Chi Fong - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 4 Stamford Plaza 107 Elm Street, 9 th Floor Stamford, Connecticut 06902 (A ...